Comparison of the effects of a cell saver and low-dose aprotinin on blood loss and homologous blood usage in patients undergoing valve surgery

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 15, Issue 3, 2001, Pages 326-330

  Tempe, Deepak K ^a   Banerjee, Amit ^a   Virmani, Sanjula ^a   Mehta, Navneet ^a   Panwar, Sunil ^a   Tomar, A S ^a   Ghambeer, D K S ^a   Nigam, M ^a  

^a G B PANT HOSPITAL   (India)

Author keywords

Aprotinin; Cardiac surgery; Cell saver

Indexed keywords

APROTININ; HEMOGLOBIN;

ADULT; ARTICLE; BLEEDING; BLOOD SAMPLING; BLOOD STORAGE; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CELL SAVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DRUG EFFICACY; FEMALE; HEART VALVE SURGERY; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TECHNIQUE;

EID: 0034992346     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1053/jcan.2001.23282     Document Type: Article

References (38)

1. Autologous blood donation prior to elective cardiac surgery: Safety and effect on subsequent blood use
2. Blood conservation in small adults undergoing valve surgery
3. Conventional blood conservation techniques in 500 consecutive coronary artery bypass operations
4. High-dose aprotinin therapy: A review of the first five years' experience
5. A comparison of the effects of tranexamic acid and low-dose aprotinin on blood loss and homologous blood usage in patients undergoing cardiac surgery
6. Beneficial effect of both tranexamic acid and aprotinin on blood loss reduction in reoperative valve replacement surgery
7. Cost benefit and efficacy of aprotinin compared with ε-aminocaproic acid in patients having repeated cardiac operations
8. Effects of intraoperative plasmapheresis on blood loss in cardiac surgery
9. Reduction in blood loss and blood use after cardiopulmonary bypass with high-dose aprotinin (Trasylol)
10. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization
11. Aprotinin therapy for reoperative myocardial revascularization: A placebo-controlled study
12. Randomised placebo-controlled double-blind study of two low-dose aprotinin regimens in cardiac surgery
13. Randomized, placebo-controlled, double-blind study of an ultra-low-dose aprotinin regimen in reoperative and/or complex cardiac operations
14. Platelet function during cardiac surgery and cardiopulmonary bypass with low-dose aprotinin
15. Effect of low-dose aprotinin on coagulation and fibrinolysis in cardiopulmonary bypass
16. Effect of recombinant aprotinin on platelet activation in patients undergoing open-heart surgery
17. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass
18. Haemostasis in patients undergoing extracorporeal circulation: The effect of aprotinin (Trasylol)
19. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass
20. Pharmacokinetics of aprotinin in preoperative cardiac surgical patients
21. Differential redistribution of platelet glycoproteins Ib and IIb/IIIa after plasmin stimulation
22. High-dose aprotinin in cardiac surgery: Three years' experience in 1784 patients
23. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass
24. Low-dose aprotinin also allows reduction of blood loss after cardiopulmonary bypass
25. Effects of low-dose aprotinin on coagulation and fibrinolysis in cardiopulmonary bypass
26. Low-dose aprotinin in internal mammary artery bypass operation contributes to important blood saving
27. Low-dose aprotinin for reduction of blood loss after cardiopulmonary bypass
28. Low-dose aprotinin as blood saver in open heart surgery
29. The use of ultra-low-dose aprotinin to reduce blood loss in cardiac surgery
30. Intraoperative autotransfusion in cardiac operations: Effect on intraoperative and postoperative transfusion requirements
31. The use of low-dose aprotinin, ε-aminocaproic acid or tranexamic acid for prevention of mediastinal bleeding in patients receiving aspirin before coronary artery bypass operations
32. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: A metaanalysis of clinically relevant endpoints
33. Formation of cytokines by retransfusion of shed whole blood
34. Intraoperative coronary thrombosis in association with low-dose aprotinin therapy
35. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor blood transfusion in patients undergoing repeat coronary artery bypass grafting
36. Aprotinin for coronary artery bypass grafting: Effect on postoperative renal function
37. Aprotinin in primary valve replacement and reconstruction: A multicenter, double-blind, placebo-controlled trial
38. Long-term follow-up of aprotinin-specific immunoglobulin G antibodies after cardiac operations